Noxopharm Nature Immunology Paper Reveals Science Behind Sofra Immune System Platform

The Groundbreaking Discovery in Nature Immunology

Australian biotech innovation has taken a significant step forward with the recent publication in Nature Immunology of a paper detailing the science behind Noxopharm's Sofra platform. This research, led by Professor Michael P. Gantier from the Hudson Institute of Medical Research, uncovers how ultra-short RNA fragments—specifically 2′-O-methyl-guanosine (2′-OMe-guanosine) modified oligonucleotides—act as natural antagonists to Toll-like receptors 7 and 8 (TLR7 and TLR8). These receptors are key players in the innate immune system, sensing viral RNA to trigger inflammation, but their overactivation can lead to autoimmune diseases.

The paper, titled "2′-O-Methyl-guanosine RNA fragments antagonize TLR7 and TLR8 to limit autoimmunity," reveals a previously unknown immune checkpoint mechanism. During the normal breakdown of host ribosomal RNA (rRNA), tiny fragments (just 1-3 nucleotides long) with 2′-OMe modifications bind to a specific antagonistic pocket on TLR7 and TLR8, preventing them from mistakenly attacking the body's own cells. This discovery explains why apoptotic cell clearance doesn't typically trigger autoimmunity and provides a blueprint for new therapies.

Hudson Institute, closely affiliated with Monash University, spearheaded this work, highlighting the pivotal role of Australian higher education institutions in translational research. Collaborators spanned multiple universities, demonstrating the power of interdisciplinary academic partnerships in biotech advancement.

Decoding TLR7 and TLR8: The Immune Sensors at the Core

Toll-like receptors (TLRs) are a family of pattern recognition receptors (PRRs) on immune cells like dendritic cells and macrophages. TLR7, primarily in endosomes, detects single-stranded RNA rich in guanosine and uridine, while TLR8 prefers uridine-rich sequences. Upon binding RNA via two agonist sites—Site 1 for nucleosides and Site 2 for short motifs—they dimerize, recruit adaptor proteins like MyD88 (myeloid differentiation primary response 88), and activate NF-κB (nuclear factor kappa B) and IRF7 (interferon regulatory factor 7) pathways. This cascade produces pro-inflammatory cytokines such as TNF-α (tumor necrosis factor alpha), IL-6 (interleukin-6), and type I interferons.

In healthy individuals, this response combats viruses. However, in autoimmunity, self-RNA from dying cells mimics viral RNA, leading to chronic inflammation. The Nature Immunology paper identifies a third site—an antagonist pocket—where 2′-OMe-guanosine at the 5′ end of short RNAs docks, stabilizing an open, inactive dimer conformation. Cryo-electron microscopy (cryo-EM) structures confirm hydrophobic interactions with residues like phenylalanine 507 in TLR7, mutually exclusive with agonist binding.

Key Scientific Insights from the Collaborative Research

The study screened hundreds of synthetic 3-mer oligonucleotides, identifying those with 5′-2′-OMe-guanosine (e.g., mGmUmC) as potent inhibitors. In cell lines like HEK293 and primary human plasmacytoid dendritic cells (pDCs), these reduced cytokine production by 80-90% in response to agonists like R848. In vivo, phosphorothioate-modified versions (PS) alleviated psoriasis-like symptoms in Aldara-treated mice, shrinking spleen size and cutting IL-6 levels.

Endogenous validation showed fibrillarin knockdown (reducing 2′-OMe marks) boosted TLR7 activation, confirming rRNA fragments as natural brakes. Patient mutations (e.g., TLR7 F507S) impair binding, linking to systemic lupus erythematosus (SLE). This multi-perspective approach—cellular assays, structural biology, animal models, and human genetics—exemplifies rigorous academic science.

Australian Universities Driving the Innovation

This isn't just a biotech story; it's a triumph for Australian higher education. Hudson Institute researchers, dual-affiliated with Monash University's Department of Molecular and Translational Science, led functional studies. The Australian National University (ANU) contributed cryo-EM and molecular dynamics via Research School of Biology experts like Ben Corry. University of Sydney's Sydney Analytical Core provided biophysical validation, while Western Sydney University handled RNA dynamics.

CSIRO's Geelong team added veterinary insights, and international input from University of Tokyo refined structures. Such collaborations underscore how university labs translate fundamental biology into therapies, fostering PhD training and postdoc opportunities in immunology and structural biology. For aspiring researchers, this highlights pathways in higher ed research jobs bridging academia and industry.

Translating Discovery: The Heracles Clinical Trial

Noxopharm, an ASX-listed Sydney-based firm, in-licensed the IP from Hudson, birthing the Sofra platform (Short Oligonucleotide Fragments for RNA modulation). Their lead, SOF-SKN—a topical 3-mer cream—was tested in the Heracles Phase 1 trial for cutaneous lupus erythematosus (CLE), safely applied to patients. No serious adverse events, paving for Phase 2 in psoriasis and rheumatoid arthritis.

CEO Dr. Gisela Mautner noted the paper "validates Sofra on solid foundations," positioning it for broader autoimmune indications. This academia-industry synergy exemplifies how university discoveries fuel clinical progress, creating demand for skilled graduates in drug development.

Sofra Platform: Applications Beyond Autoimmunity

Sofra's versatility shines: SOF-VAC mitigates mRNA vaccine reactogenicity by curbing TLR7-driven cytokines, enhancing safety for future pandemics. In oncology, it could temper chronic inflammation aiding tumors. Ultra-short design ensures tissue penetration, stability via PS backbones, and low immunogenicity.

• Targeted antagonism without broad immunosuppression
• Synthetic scalability for manufacturing
• Potential in vaccine adjuvants or anti-virals

For Australian unis, this opens grants in nucleic acid therapeutics, with NHMRC funding already supporting similar work.

Autoimmune Burden in Australia and Research Impacts

Australia faces a rising autoimmune tide: ~5% prevalence (1 million+ affected), with rheumatoid arthritis in 514,000. Women bear 78% burden, costs exceeding $AUD 10B yearly in healthcare/productivity. Lupus hits 20,000, psoriasis 500,000. Sofra-like therapies promise precision, reducing steroid reliance.

Higher ed responds via specialized programs; Monash's immunology courses train the next wave, linking to research assistant careers.

Funding, Challenges, and Stakeholder Perspectives

NHMRC Ideas Grants, mRNA Victoria, and Noxopharm backed this (e.g., $2M+). Challenges: Scaling synthesis, delivery beyond skin, mutation variability. Gantier: "Shortest functional RNAs ever—game-changer." Industry views it as $100B market entry.

Universities gain prestige, patents, spin-offs, boosting research jobs.

Photo by Devesh Thapa on Unsplash

Future Outlook: Reshaping Immunology Research

Phase 2 trials loom, with Sofra eyeing systemic delivery. Unis like ANU eye AI for oligo design. Implications: New PhD foci in RNA epigenetics, international collabs. Actionable: Explore scholarships in biotech; track ASX:NOX for partnerships.

In summary, this paper cements Australia's higher ed as immunotherapy leader. Aspiring academics, check higher ed jobs, research jobs, and career advice to join. For prof feedback, visit Rate My Professor.